SLAS 2024 – Boston

Speaking session

Title: Easy Kinome Profiling: Synergy of Carna Bioscience’s® Biotinylated Kinases and Carterra’s® HT-SPR™

Speaker: Adam Shutes, PhD, Carna Biosciences

Date and Time: Monday, February 5, 2024 | 2:00 – 2:20 PM EST

Location: Solutions Spotlight Theater (Exhibition 1290)

Abstract: Kinases are an attractive target class across many therapeutic areas. To dig deeper into this target class, mechanisms beyond ATP-competition are actively under investigation including allosteric inhibition, degradation, or as partners in molecular glues.

For these approaches, standard activity assays and even advanced enzymology can only go so far in providing sufficient detail to inform chemistry decisions. Direct label-free approaches, such as SPR binding, provide the intrinsic kinetics of interactions which allow differentiation of compounds and compound series that, although potentially similar in activity assays, ultimately show distinct kinetics. Critically these different mechanisms can have an impact on efficacy in humans.

In this talk we will present the benefits of kinase profiling via HT-SPR technology. Straightforward assay development, enabled by high quality biotinylated kinases, supported rapid screening of a library of small molecule compounds against 87 different kinases. By measuring 384 binding events per cycle, over 80,000 interactions were characterized in a 3-day run. Initial screening data combined with more detailed follow up assays provided a wealth of deep kinetic data which correlated well to activity data thus validating the accuracy of Carterra’s LSA^XT platform as well as the quality, activity, and stability of Carna’s biotinylated kinases.

Title: Meeting Scalability Demands for Label-Free Binding Assays in an Evolving Research Landscape

Speaker: Noah T. Ditto, Technical Product Manager, Carterra

Date and Time: Wednesday, February 7, 2024 | 12:00 – 12:20 PM EST

Location: Solutions Spotlight Theater (Exhibition 1290)

Abstract: Drug discovery is undergoing a transformation across many fronts from the implementation of generative AI approaches to the growing resurgence in omics-based strategies as well as the emergence of novel therapeutic modalities. What remains constant however is the fundamental need to deliver high-quality, impactful data in less time using less resources. The historical paradigm of either focusing on either speed or depth of data has resulted in a myriad of assays that excel in one of these areas but under-deliver in the other. Real-time, label-free binding studies using biosensors are no exception and have long been a technology space that while rich in data outputs could never match the throughput requirements of robust research workflows.

HT-SPR, however, is re-writing the way real-time, label-free binding assays are deployed in modern discovery environments. With the ability to screen samples across the spectrum of small molecules to mAbs and approaching 150,000 detailed binding interactions in a single experiment, the Carterra LSA^XT operates at an unmatched scale for binding characterization. Importantly, these capabilities come with less resource requirements than any other platform owing to the novel microfluidics of the LSA^XT. This talk will highlight the unique advantages of using HT-SPR for highly scaled, real-time, label-free binding with examples across multiple sample types and most importantly how these measurements impact the intelligent selection of drug candidates.